NCT07931053
Use of mHealth Application and Education to Increase Appropriateness of Thromboprophylaxis in Patients With Cancer
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below.
- Minor Secondary endpoints: details revised at 3 of 3 entries
- Study First Submitted
- Minor: routine updates
Endpoints
Primary
Secondary (3)
Arms and interventions
Inclusion criteria: * Age 18 or oler * Recent diagnosis of solid tumor or disease progression after partial or complete remission. * Starting a new course of systemic anticancer therapy-chemotherapy, targeted therapy, hormone therapy, or immunotherapy-planned to last at least 3 months. Exclusion criteria: * High risk of bleeding (e.g., advanced liver disease with coagulopathy) * Life expectancy of less than 3 months * Hematologic malignancy * Estimated glomerular filtration rate below 30 mL/min/1.73 m² * Platelet count below 50,000/mm³ * Weighed less than 40 kg * Currently receiving anticoagulation. In the preintervention period, The investigators reviewed the electronic medical records of patients with a recent cancer diagnosis who were seen between January and June 2024.
After using the mHealth application, the treating physician made the final decision regarding use of thromboprophylaxis after considering risk of thromboembolic disease, bleeding risk, renal function, drug interactions, and patient preferences. Postintervention period. For patients with cancer seen between January and June 2025, the investigators collected the same variables from the electronic medical records as in the preintervention period. The investigators selected the same calendar months to control for seasonality and enhance comparability between periods
Other: mHealth application, Education. Guideline review
Sites
1 site in 1 country
- Hospital Marina BaixaVillajoyosa, Alicante, Spain